Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) Director Ali Behbahani bought 12,000,000 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The shares were purchased at an average cost of $1.67 per share, for a total transaction of $20,040,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

NASDAQ ADAP opened at $11.19 on Thursday. The company has a market cap of $998.92 million, a price-to-earnings ratio of -13.84 and a beta of 1.09. Adaptimmune Therapeutics PLC – has a 1-year low of $6.60 and a 1-year high of $14.63.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.20). The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $7.76 million. Adaptimmune Therapeutics had a negative net margin of 191.14% and a negative return on equity of 47.22%. equities research analysts predict that Adaptimmune Therapeutics PLC – will post -1.02 EPS for the current fiscal year.

ADAP has been the topic of a number of recent research reports. Zacks Investment Research raised Adaptimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 7th. BidaskClub downgraded Adaptimmune Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, July 21st. Leerink Swann lifted their target price on Adaptimmune Therapeutics to $20.00 and gave the stock an “outperform” rating in a research report on Monday, June 4th. TheStreet downgraded Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, July 16th. Finally, ValuEngine raised Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 1st. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $16.94.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Arbitrage SA acquired a new stake in Adaptimmune Therapeutics during the second quarter valued at approximately $122,000. BB&T Securities LLC acquired a new stake in Adaptimmune Therapeutics during the second quarter valued at approximately $128,000. Jane Street Group LLC acquired a new stake in Adaptimmune Therapeutics during the first quarter valued at approximately $168,000. Trexquant Investment LP acquired a new stake in Adaptimmune Therapeutics during the second quarter valued at approximately $178,000. Finally, Trellus Management Company LLC acquired a new stake in Adaptimmune Therapeutics during the second quarter valued at approximately $195,000. 59.32% of the stock is currently owned by institutional investors.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.

Recommended Story: How are Outstanding Shares Different from Authorized Shares?

Insider Buying and Selling by Quarter for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.